The Hormetic Dose

Because for a whole class of mechanisms the small amount is the active one, and a trial-sized amount would be a different intervention rather than a stronger one. That is the short answer. The arithmetic behind the objection is correct and is published here rather than avoided: a 25 g jar is 72 servings, so a serving of 1/8 teaspoon is roughly 347 mg of finished concentrate, divided across a median of 35 graded ingredients. Anyone dividing those numbers will conclude the per-ingredient amounts sit far below the trials, and they will be right. What does not follow is the hidden premise in the objection: that the dose–response curve always rises with the amount.

A stress small enough to survive leaves the cell better defended than before. The name is old and plain: a small, well-judged stress teaches a living system to defend itself against a large one. The defining feature is the shape of the curve. The response is biphasic — an inverted U — so that past a point more of the compound does less, not more. That shape is not a special pleading invented here; it is the subject of a published experimental review, Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence (doi 10.3390/jcm9030718).

Nor is the shape rare. The hormesis database, assembled from the published toxicological literature, holds 2,527 citations carrying 8,962 hormetic dose responses — close to nine thousand separate measured endpoints showing the same inverted U. That is the weight of evidence behind the curve itself, independent of any ingredient in this catalog. The hormesis database: The occurrence of hormetic dose responses in the toxicological literature, Calabrese & Blain, Regulatory Toxicology and Pharmacology 2011;61(1):73–81, doi 10.1016/j.yrtph.2011.06.003.

Fasting. It is the same argument in a form most people already grant: the benefit is not in going without food, it is in the response the body mounts against it. The review that defines that field states that cells respond to intermittent fasting “by engaging in a coordinated adaptive stress response”, and that the practice “elicits evolutionarily conserved, adaptive cellular responses” — de Cabo & Mattson, New England Journal of Medicine 2019;381:2541–2551, doi 10.1056/NEJMra1905136. That review does not use the word hormesis, and is not cited here as if it did; the biphasic curve is sourced above. What fasting supplies is the principle in a form a reader can check against their own experience — a stress small enough to survive leaves the system better defended, and more of it is not better. The nine fasting practices this catalog maps, each with its own evidence, are set out in Fasting.

Seven, each with its mechanism named and its evidence graded on its own page:

• Lithium orotate — the clearest inverted-U in this set: in fruit flies a low amount extends lifespan by 16–18% and a high amount shortens it. Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis, PMID 27068460.
• Green tea polyphenols (EGCG) — the canonical mitohormetic: in roundworms EGCG extends lifespan through stress-triggered mitochondrial building, and the effect vanishes without the genes that route it. The genetic control is what makes this one load-bearing: remove the mechanism and the benefit disappears.
• Glucosamine — a genuine mitohormetic, and a surprise in a joint ingredient. D-Glucosamine supplementation extends life span of nematodes and of ageing mice, doi 10.1038/ncomms4563.
• Sulforaphane (from Brassica oleracea) — the prototypical NRF2 hormetin, whose dose–response is a clear inverted-U. Human data exist for the mechanism: Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes, doi 10.1126/scitranslmed.aah4477.
• Curcumin — engages three separate defense systems at once, and its curve is biphasic: past a point, more of it present does less, not more.
• Berberine — mimics energy stress through AMPK to provoke an adaptive response, a measured biphasic effect.
• Icariin (from Epimedium) — a recognised hormetin: extends roundworm lifespan and stress tolerance through the insulin-signaling route.

No — and the lithium result is the cleanest demonstration, because the same compound in the same animal runs both directions. A low amount extends lifespan by 16–18%; a high amount shortens it. On a curve of that shape, scaling a hormetin up to the amount used in a single-ingredient trial does not buy a larger effect. It can buy the opposite one. For these ingredients the small amount is a design decision with a published rationale, not a shortfall against a target.

Yes, and there is a measured mechanism for it rather than an inferred one. 5′-methoxyhydnocarpin has no antimicrobial activity by itself at any concentration above 500 µg/ml. At 10 µg/ml it cut berberine’s minimum inhibitory concentration against Staphylococcus aureus from 256 to 16 µg/ml — a sixteen-fold potentiation — by inhibiting the NorA efflux pump that would otherwise expel berberine from the cell. Both compounds occur in the same Berberis plant. Stermitz et al., PNAS 2000, 97(4):1433–1437, doi 10.1073/pnas.030540597.

They are the same design argued from two directions. Convergence says a formula is solved to cover a named pathway set rather than to out-dose any single ingredient. Hormesis says that for a class of those ingredients, covering the pathway at a small amount is not a compromise on the way to a larger one — it is the amount at which the mechanism operates. Coverage explains the breadth of a roster; hormesis explains the size of each share.

It stops in four places, and they are the reason this page exists rather than a marketing claim.

• It does not apply to every ingredient. Seven documented hormetins is seven, not a whole roster. Where an ingredient’s evidence is a straightforward dose-dependent human trial, a smaller amount is a smaller amount, and nothing on this page changes that.
• Much of the hormesis evidence is in model organisms. Roundworms, fruit flies and mice are where several of these results live. The sulforaphane glucose-control work is human; the lifespan work is not.
• The potentiation case is in vitro. It is antibacterial MIC testing. Nothing in it establishes the same effect after oral dosing in a person.
• None of it is evidence about a finished formula. 0 of 68 formulas here have been trialed as a complete product. These arguments explain why the design is not arbitrary. They are not a claim that any particular jar reproduces any particular result.

It does not claim synergy. Synergy is a specific pharmacological claim — an effect greater than the sum of the parts, demonstrated by combination index, isobologram or factorial design — and no formula here has been tested that way. It does not claim that a milligram fraction of any ingredient reproduces the trial that earned that ingredient its grade. It does not claim that the product treats, cures or is clinically proven for any goal. It claims one thing: that the published dose–response literature does not support the assumption that more of a phytochemical is always more of its effect, and that the amounts in these formulas were chosen with that literature in view. The per-ingredient milligram breakdown is not published, and it is recorded in the Limits Register.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.